Tracheoesophageal fistula in a treatment naive patient with lung cancer
Malignant tracheoesophageal fistula (TEF) is a serious complication of thoracic malignant diseases and is more common in esophageal cancer than in lung cancer (1, 2) . The largest study evaluating patients with malignant TEF and bronchoesophageal fistula reported an incidence of 0.16% in 5714 patients with lung cancer (3) . Patients with TEF typically presents with coughing and shortness of breath due to aspiration of food and saliva. Recurrent respiratory infections and malnutrition leads to rapid deterioration. Life expectancy is estimated at about six weeks without proper and prompt treatment (4) . In lung cancer patients, new interventions such as combination chemoradiotherapy and anti-angiogenesis agents lead to an increased risk for the development of TEF (5). Herein we would like to present a treatment naive patient with advanced stage pulmonary adenocarcinoma and TEF.
A 44-year-old male patient was admitted to our clinic with chest pain, cough, dyspnea, and difficulty in swallowing. He was diagnosed as pulmonary adenocarcinoma by percutaneous needle biopsy from the mass lesion in the right upper lobe, and was consulted to our clinic for fiberoptic bronchoscopy (FOB). He was receiving palliative cranial radiotherapy for cranial metastasis. Computed tomography (CT) of the thorax demonstrated a mass lesion in right upper lobe with a largest diameter of 7 cm and enlarged conglomerated mediastinal lymph nodes. A TEF tract was seen both on axial and sagittal CT images ( Figure 1 ). FOB and upper gastrointestinal endoscopy revealed a large TEF (Figure 2 ). Since TEF was located in the proximal part of the esophagus, the patient was not found suitable for esophageal stenting. A percutaneous endoscopic gastrostomy (PEG) was performed and he was referred to an interventional pulmonology clinic for the insertion of a tracheal stent after the first cycle of chemotherapy that was applied without any serious complication.
The management of malignant TEF is primarily palliative in terms of quality of life. The therapeutic aim should be restoring the patency of the trachea and enabling the patient to be nourished. Surgery is usually considered inappropriate in malignant TEF, as the patients tend to be in poor performance status and near the end of their lives (6). Airway and esophageal stenting are safe procedures and beneficial for symptomatic relief. Some papers report high success rates in double stenting (7) . When it is difficult to place double stent at the same time, a tracheal stent has priority, because an esophageal stent alone may compress the trachea and elicit respiratory distress. Plastic and silicone-cuffed stents were initially used in the management of TEF (8, had airway stents, 37 had esophageal stents and 10 had double stenting as their primary intervention. The quality of life scores were significantly improved after stenting in all three groups. However the survival was significantly lower in patients who received only airway stents (11) .
The American College of Chest Physicians guidelines recommended double stenting of the esophagus and airway or esophageal stenting with SEMS. They make a remark at the sequence of stenting. They suggested that the airway stent should be placed prior to the esophageal stent to minimize the risk of airway compromise if the esophageal stent is placed first (6) . PEG is an alternative procedure that can be considered in palliative treatment of TEF (12) . Our patient was not suitable for esophageal stenting. Since he was young and was in good performance status, we prefer to perform PEG for effective nutrition and tracheal stenting for prevention of aspirations of saliva.
